RayKnowChina Research Map
Shortlist

RecruitingGliomaPhase 2

Registered title, quoted from ClinicalTrials.gov

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

An open trial on glioma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06595186, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients newly diagnosed with glioblastoma either by imaging or pathology testing, Gross total resection equal to or greater than 80%.

    Inclusion criterion 2

  3. Patient receiving prohibited medications and that cannot be discontinued at least 2 weeks prior to the start of treatment.

    Exclusion criterion 7

  4. Karnofsky score ≥ 70.

    Inclusion criterion 5

  5. Women who are pregnant or Breast-feeding. 11 Positive human immunodeficiency virus antibody, active hepatitis B virus infection, or active hepatitis C virus infection.

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06595186, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion

Participants must meet all the following criteria to be eligible for randomization into the study:

  • Male or female aged ≥18 years and ≤75 years.
  • Patients newly diagnosed with glioblastoma either by imaging or pathology testing, Gross total resection equal to or greater than 80%.
  • Patients must finish concurrent chemo-radiotherapy (CCRT) no sooner than 4 weeks and no later than 6 weeks.
  • Stable dose or reduced dose of corticosteroid for more than 2 weeks.
  • Karnofsky score ≥ 70.
  • Life expectancy \> 12 weeks.
  • Adequate biological function.
  • Men or women should be using adequate contraceptive measures during the study and for 6 months following the last dose of investigational product.
  • Sign and date the informed consent form prior to the start of any study-specific qualification procedures.
  • MGMT unmethylation (only for Dose Expansion Cohort).

Exclusion

Participants who meet any of the following criteria will be disqualified from entering the study:

  • Patients who received anti-tumor therapy except for concurrent chemo-radiotherapy (CCRT).
  • Patient diagnosed with brain stem and spinal cord tumor as the primary tumor.
  • Hypersensitivity to any ingredient of JK-1201I.
  • Severe, uncontrolled or active cardiovascular diseases within the past 6 months.
  • Inability to take medication by oral or presence of clinically significant gastrointestinal abnormalities that may affect absorption of investigational product.
  • Uncontrolled seizures.
  • Patient receiving prohibited medications and that cannot be discontinued at least 2 weeks prior to the start of treatment.
  • Severe or uncontrolled high blood pressure.
  • Unresolved toxicity from prior anti-tumor therapy.
  • Women who are pregnant or Breast-feeding. 11 Positive human immunodeficiency virus antibody, active hepatitis B virus infection, or active hepatitis C virus infection.
  • Have participated in another clinical trial within 4 weeks prior to informed consent form.
  • History of mental disorders. 14. Other conditions that the investigator considers unsuitable to participate in this clinical trial.

Quoted from ClinicalTrials.gov, NCT06595186, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06595186, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06595186